To investigate whether SOX30 methylation was a potential biomarker in the surveillance of AML, we examined SOX30 methylation level in different clinical stages of AML patients (49 patients achieved CR and 27 relapsed patients). Here, SOX30 is linked to acute myeloid leukemia.